Similar articles

• Perspectives in the clinical management of BRCA mutations carriers.

  Savarese A, Cognetti F. Savarese A, et al. J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):31-5. J Exp Clin Cancer Res. 2002. PMID: 12585651 Review.
• Improving surveillance and quality of life of BRCA mutation carriers.

  Loman N, Borg A. Loman N, et al. J Clin Oncol. 2010 Aug 1;28(22):e376-7. doi: 10.1200/JCO.2010.28.7334. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458044 No abstract available.
• Risk reduction works for BRCA mutation carriers--with heavy costs.

  Vanchieri C. Vanchieri C. J Natl Cancer Inst. 2005 Jul 20;97(14):1032-3. doi: 10.1093/jnci/dji228. J Natl Cancer Inst. 2005. PMID: 16030299 No abstract available.
• Prevention and management of hereditary breast cancer.

  Narod SA, Offit K. Narod SA, et al. J Clin Oncol. 2005 Mar 10;23(8):1656-63. doi: 10.1200/JCO.2005.10.035. J Clin Oncol. 2005. PMID: 15755973 Review. No abstract available.
• Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

  Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Rabban JT, et al. Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a. Am J Surg Pathol. 2009. PMID: 19440148